EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review

Timo T Moscou iD, Selene R T Veerman iD

Therapeutic Advances in Psychopharmacology · 2024-01 · 14

DOI: 10.1177/20451253241302603 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 07.12.2024. Verfasst von Timo T Moscou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Mental Health, Mental Health Service Noord-Holland Noord, Alkmaar, Oude Hoeverweg 10, Noord Holland 1816 BT, The Netherlands. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extant research on cognitive functioning in treatment-resistant schizophrenia (TRS) is limited and of poor quality. Cognitive impairments in patients with schizophrenia spectrum disorders (SSD) significantly influence quality of life. In patients with TRS, clozapine (CLO) is not consistently associated with improved cognitive functioning. The active metabolite n-desmethylclozapine (norclozapine (NCLO)) potentially exerts procognitive effects due to cholinergic and glutamatergic activity. Unfortunately, research on CLO/NCLO ratio and cognitive functioning is even more scarce.

Objectives

To review the literature on the effect of the CLO/NCLO ratio on cognitive functioning in patients with SSD.

Design

This is a systematic review. A search was carried out in the electronic databases Embase, PsycINFO, PubMed, Cochrane and the Cochrane Controlled Register of Trials with no restrictions in language or publication year.

Results

We identified 15 relevant studies (longitudinal, k = 4; cross-sectional, k = 11). The study population consisted of adult clozapine users ( n = 953) with varying degrees of treatment resistance. Specific cognitive domains and overall cognitive functioning were assessed using various neuropsychological tests and a composite score, respectively. Eleven studies were considered of fair quality (longitudinal: k = 2, cross-sectional: k = 9). In one longitudinal study, a negative causal relationship was found between the CLO/NCLO ratio and attention/vigilance and a negative correlation between social cognition and the composite score ( n = 11). No significant correlations were found between the CLO/NCLO ratio and the cognitive domains processing speed, reasoning/problem solving, or for working memory ( k = 1, n = 11), verbal learning ( k = 1, n = 43) or visual learning ( k = 2, n = 54). Study designs and populations were heterogeneous, and the analysis of confounding factors was limited and inconsistent.

Conclusion

Clinical evidence is too scarce to support the hypothesis of a procognitive effect of NCLO. Personalised CLO treatment by modulating the CLO/NCLO ratio remains a distant prospect. Recommendations for future CLO research and anticipated limitations are discussed.

Trial registration

This systematic review was preregistered with PROSPERO (CRD42023385244).

Schlagwörter

Stichwörter der Autor:innen

clozapinecognitionnorclozapineplasma levelratioschizophrenia spectrum disordersystematic review

Autor:innen und Institutionen

  • Department of Community Mental Health, Mental Health Service Noord-Holland Noord, Alkmaar, Oude Hoeverweg 10, Noord Holland 1816 BT, The Netherlands.
  • Department of Community Mental Health, Mental Health Service Noord-Holland Noord, Alkmaar, The Netherlands.
  • Dutch Clozapine Collaboration Group, Oegstgeest, The Netherlands.

ORCID-Profile: Timo T Moscou, Selene R T Veerman

Zitieren

APA

Moscou, T. T., & Veerman, S. R. T. (2024). Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review. Therapeutic Advances in Psychopharmacology, 14. https://doi.org/10.1177/20451253241302603

Vancouver

Moscou TT, Veerman SRT. Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review. Therapeutic Advances in Psychopharmacology. 2024;14. doi:10.1177/20451253241302603

BibTeX
@article{Moscou2024,
  author = {Moscou, Timo T and Veerman, Selene R T},
  title = {Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2024},
  volume = {14},
  doi = {10.1177/20451253241302603}
}
Kostenlos starten →